A primer on concentrated insulins: what an internist should know.

Autor:	Barnosky A; a Wheaton Franciscan Healthcare - Endocrinology , Wauwatosa , WI , USA., Shah L; b Loyola University Medical Center Ringgold Standard Institution - Endocrinology , Maywood , IL , USA., Meah F; c Edward Hines Junior VA Hospital Ringgold Standard Institution - Endocrinology , Hines , IL , USA., Emanuele N; c Edward Hines Junior VA Hospital Ringgold Standard Institution - Endocrinology , Hines , IL , USA., Emanuele MA; d Loyola University Medical Center - Endocrinology , Maywood , IL , USA., Mazhari A; b Loyola University Medical Center Ringgold Standard Institution - Endocrinology , Maywood , IL , USA.
Jazyk:	angličtina
Zdroj:	Postgraduate medicine [Postgrad Med] 2016 May; Vol. 128 (4), pp. 381-90. Date of Electronic Publication: 2016 Mar 17.
DOI:	10.1080/00325481.2016.1159909
Abstrakt:	The common insulin concentration in most preparations of insulin is 100 units per mL or U-100. Human regular U-500 insulin was the first concentrated insulin introduced and it has been available in the United States since the 1950s. Humulin R is the only human regular U-500 available on the market. Human regular U-500 is five times more concentrated than U-100 and because of its pharmacodynamic properties, works as both a basal and a bolus insulin. Human regular U500 allows for delivery of a larger insulin dose with a smaller volume leading to better absorption compared to U-100 and has traditionally been used in patients with moderate to severe insulin resistance. More recently other forms of concentrated insulin have become available and the newer concentrated insulin preparations can be used in diabetic patients with or without insulin resistance. Our intent is to provide primary care physicians with a review of the pharmacology and current literature on concentrated insulins as well as recommendations for patient selection, dose initiation, and dose adjustment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu